Validation of downstream processes

Mammalian Cell Biotechnology in Protein Production

Volumn , Issue , 2011, Pages 453-482

  Walter, Joachim ^a   Allgaier, Hermann ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85064616991     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. Ad Hoc Working Party on Biotechnology/Pharmacy, Commission of the European Communities, Biotech headings for Notice to Applicants, Part II, 1992
2. Ad Hoc Working Party on Biotechnology/Pharmacy (1991) Note for Guidance: Validation of Virus Removal and Inactivation procedures, EC DG 111/8115/89-EN 1991
3. Allgaier, H. (1994) Requirements and Validation of a Biotech Multipurpose Plant. Chimia 48, 464-466
4. Allgaier, H. (1996) Conversion of a Biotech Facility to "Multi-Use" Operation. In: Pharmaceutical Biotechnology Internationl (Barnacal, P.A., ed.), Sterling Publications Limited, London W2 1XR, pp 47-48
5. American Society for Testing and Materials (ASTU) (1988) Draft Standard Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products, Philadelphia
6. Bader, F. G., Blum, M., Garfinkle, B.D., MacFarlane, D., Massa, T. and Copmann, T. L. (1992) Multiuse Manufacturing Facilities for Biologicals, Biopharm Sept. 1992, 32-40
7. Baffi, R., Dolch, G., Garnick, R., Huang, Y.F., Mar, B., Matsuhiro, D., Niepelt, B., Parra, C. and Stephan, M. (1991) A Total Organic Carbon Analysis for Validation Cleaning Between Products in Biopharmaceutical Manufacturing, Journal of Parenteral Science & Technology, «, 1 3-1 9
8. Bergemann, K., Walter, J. and Berthold, W. (1993) Removal of Host Cell DNA from Protein Solutions, presented at: Validation of Pharmaceuticals and Biopharmaceuticals. Parenteral Drug Associates, Inc. (PDA), 2nd International Congress Basel 22-24 February, 1993 and the PDA Workshops, 25-27 February, 1993
9. Berthold, W., Walter, J. and Werz, W. (1992) Experimental approaches to guarantee minimal risk of potential virus in purified monoclonal antibodies, Cytotechnology 9, 189-201
10. Bill, E., Lutz, U., Sparrmann, M., and Allgaier, H. (1995) Optimization of Protein G Chromatography for Biopharmaceutical Monoclonal Antibodies. Journal of Molecular Recognition 8, 90-94
11. Bouchard, L., Geiinas, C., Asselin, C. and Bastin, M. (1984) Tumorigenic activity of Polyoma virus and SV40 DNAs in newborn rodents. Virology 135, 53-64
12. Brady, D., Bonnerjea, J. and Hill, C.R. (1990) Purification of Monoclonal Antibodies for Human Clinical Use: Validation of DNA and Retroviral Clearance. In: Separations For Biotechnology 2, SCI, Elsevier Applied Science, London-New York
13. Commission of the European Communities (1989) Guidelines on the Quality, Safety and Efficacy of Medicinal Products for Human Use, Vol. 2 of The Rules Governing Medicinal Products in the European Community
14. Commission of the European Communities (1989) Guidelines to Good Manufacturing Practice for Medicinal Products of the Rules Governing Medicinal Products in the European Community, Volume 4
15. Committee for proprietary medicinal products (July 1987) Notes to applicants for marketing authorization on requirements for production and quality control of medicinal products derived by recombinant DNA technology
16. Committee for Proprietary Medicinal Products Ad Hoc Working Party on Biotechnology/ Pharmacy (June 1987) Guidelines on the Production and quality control of monoclonal antibodies of murine origin intended for use in man
17. Committee for Proprietary Medicinal Products Ad Hoc Working Party on Biotechnology/ Pharmacy (July 1990) Guidelines on the production and quality control of human monoclonal antibodies
18. Council of Europe (1990) European Pharmacopeia
19. Division of Manufacturing and Product Quality, FDA (1987) Guidelines on General Principles of Process Validation
20. Division of Manufacturing and Product Quality, FDA (1987) Guidelines on Sterile Drug Product Produced by Aseptic Processing
21. EC-Commission, Notes to applicants for marketing authorization, DG III/860/86-EN (1986) Guidelines on the production and quality control of medicinal products derived by recombinant DNA-technology
22. FDA, Bethesda, MD, USA (1987) Guidelines on Validation of the Limulus Amoebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products and Medical Devices
23. FDA, Center for Biologies Evaluation and Research, Bethesda, MD, USA (1987) Points to Consider in the Characterization of Cell Lines to Produce Biological Products
24. FDA, Center for Biologies Evaluation and Research, Bethesda, MD, USA (1987) Points to Consider in the Manufacture of Monoclonal Antibody Products for Human Use
25. FDA, Center for Biologies Evaluation and Research, Bethesda, MD, USA (1990) Cytokine and Growth Factor Pre-Pivotal Trial Information Package with Special Emphasis on Products Identified for Consideration under 21 CFR 312 Subpart E. Drugs Intended to Treat Life-Threatening and Severely Debilitating Illnesses
26. FDA, Center for Biologies Evaluation and Research, Bethesda, MD, USA (1991) Points to Consider in Human Somatic Cell Therapy and Gene Therapy
27. FDA, Center for Drugs and Biologies, Bethesda, MD, USA (1985) Antiviral Drugs for Non-Life-Threatening Disease: Draft Points to Consider for Safety Evaluation Prior to Phase 1 Studies
28. FDA, Office of Biologies Research and Review, 8800 Rockville Rike, Bethesda MD, 20892 USA (1987) Points to consider in the characterization of cell lines used to produce Biologicals. FDA, Office of Biologies Research and Review, Center for Drugs and Biologies, Bethesda, MD, USA (April 10,1985) Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology
29. FDA, Office of Biologies, Bethesda, MD, USA (1983) Interferon Test Procedures: Points to Be Considered in the Production and Testing of Interferon Intended for Investigational Use in Humans
30. Garnick, R.L., Solli, N.J. and Papa, P.A. (1988) The Role of Quality Control in Biotechnology: An Analytical Perspective. Anal. Chem. 60, 2546-2557
31. Health and Welfare Canada (1990) Drugs Directorate Guidelines, Manufacture and Testing of Biologies Produced by Recombinant DNA Technology
32. Health and Welfare Canada (1990) Drugs Directorate Guidelines, Utilization of Continuous Cell Lines in the Manufacture of Biologies
33. Homma, J. Y., Kanegasaki, S., Lüderitz, O., Shiba, T. and Wertphal, O. (eds.) (1984) Bacterial Endotoxin. Verlag Chemie, Weinheim, New York
34. Horowitz, B. (1989) Investigations into the application of tri(n-butyl) phosphate/detergent mixtures to blood derivatives. Virus inactivation in plasma products. Curr. Stud. Hematol. Blood Transfus., No. 56 (Mortenthaler, J.-J., ed.), pp 83-96, Karger, Basel
35. Kozak, R. (1992) Current FDA Requirements for Phase 1 Studies, Workshop on Preclinical Safety Testing of Monoclonal, Antibodies, Bethesda, MD, USA
36. Kung, V.T., Panfili, P.R., Sheldon, E.L., King, R.S., Nagainis, P.A., Gomez, B., Ross, D. A., Briggs, J. and Zuk, R.F. (1990) Picogram Quantitation of Total DNA Using DNABinding Proteins in a Silicon Sensor Based System. Anal. Biochem. 187, 220-227
37. Lees, G. and Onions, D. (1990) Validation of Downstream Processes. Technical Bulletin 4, Quality Biotech, Glasgow
38. Liptrot, C. and Gull, K. (1991) Detection of Viruses in Recombinant Cells by Electron Microscopy. In: Animal Cell Technology: Developments, Processes and Products (Spier, R.E., Griffiths, J.B. and MacDonald, C., eds.), Butterworth-Heinemann Ltd. Linacre House, Jordan Hill, Oxford 0X2 8DP, pp 653-656
39. Löwer, J. (1990) Risk of Tumor Induction In Vivo by Residual Cellular DNA: Quantitative Considerations. J. Med. Virol. 31, 50-53
40. Löwer, J. (1991) Virological Aspects of the Quality Control of Biologicals: Quantitative Considerations. In: Symposium on Virological Aspects of the Safety of Biological Products London, England, 1990. Develop, biol. Standard. 75, pp 221-226, S. Karger, Basel
41. Marcus-Sekura, C.J. (1991) Validation of Removal of Human Retroviruses. Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
42. Ministry of Health and Welfare, Japan (1988) Documents necessary for application for approval of drugs manufactured using cell culture technology
43. Minobe, S., Tadashi, S., Tetsuya, T. and Chibata, J. (1983) Characteristics of Immobilized Histamin for Pyrogen Adsorption. J. Chromatogr. 262, 193-198
44. Molecular Devices Corporation, publication 0120-0501A (1988) "Threshold Total DNA Assay". National Institutes of Health (May 7, 1986) Guidelines for Research Involving Recombinant DNA Molecules. Department of Helth and Human Services
45. Nolan, J.G., McDevitt, J.J. and Goldmann, G.S. (1975) Endotoxin binding by charged and uncahrged resin. Proc. Soc. Exp. Biol. Med. 149, 766-770
46. Novitsky, T.J. and Gould, M.J. (1985) Inactivation of Endotoxin by Polymyxin B. in: Technical Report No. 7, Parenteral Drug Association, Inc., Philadelphia
47. Office of Science and Technology Policy, Federal Register, Vol. 51, No. 123 (June 26, 1986) 23301-23750, Coordinated Framework for Regulation of Biotechnology
48. Organization for Economic Cooperation and Development (OECD) (July 16, 1986) Recombinant DNA Safety Considerations
49. Ostrove, J.M., Walsh, W., Vacante, D. and Patel, N. (1992) Molecular Hybridization Techniques and Polymerase Chain Reaction (PCR) as Methods for Safety Assessment of Animal Cells used in Biopharmaceutical Production. In: Animal Cell Technology: Developments, Processes and Products (Spier, R. E., Griffiths, J. B. and MacDonald, C., eds.), Butterworth-Heinemann Ltd. Linacre House, Jordan Hill, Oxford OX2 8DP, pp 689-695
50. Parenteral Drug Association, Inc., Philadelphia (1985) Depyrogenation, Technical Report No. 7
51. Pearson III, F. C. (1985) Pyrogens. Advances in Parenteral Sciences/2, Marcel Dekker, Inc., New York, Basel
52. Pearson III, F. C. (1987) Pyrogens and Depyrogenation, Theory and Practice. In: Aseptic Pharmaceutical Manufacturing (Olson, W.P. and Groves, M.J., eds.), Interpharm Press Inc., Prairie View
53. Per, S.R., Aversa, C.R. and Sito, A.F. (1989) Quantification of Residual DNA in Biological Products. Clinical Chemistry 35, 1859-1860
54. Prince, A.M., Stephan, W. and Brotmann, B. (1993) b-Propiolactone/Ultraviolett Irradiation: A Review of Its Effectiveness for Inactivation of Viruses in Blood Derivatives. Rev. Infect. Dis. 5, 92-107
55. Rigby, P.W.J., Dieckmann, M., Rhodes, C. and Berg, P. (1977) Labeling deroxyribonucleic acid to high specific activity in vitro by nick translation with DNA-Polymerase I. J. Mol. Biol. 113, 237-251
56. Schiff, L.J., Moore, W.A., Brown, J. and Wisher, M.H. (1992) Lot Release-Final Product Safety Testing for Biologies. Pharmaceutical Technology International, September 1992
57. Schindler, R. and Dinarello, C.A. (1990) Ultrafiltration to Remove Endotoxins and other Cytokine-Inducing Materials from Tissue Culture Media and Parenteral Fluids. Bio Techniques 8, 408-413
58. Smith, K.T., Doherty, I., Thomas, J. A., Per, S.R. and Sito, A.F. (1991) Quantitation of Residual DNA in Biological Products: New Regulatory Concerns and New Methodologies. In: Animal Cell Technology: Developments, Processes and Products (Spier, R.E., Griffiths, J.B., MacDonald, C., eds.), Butterworth-Heinemann Ltd. Linacre House, Jordan Hill, Oxford 0X2 8DP, pp 696-698
59. U.S. Government Printing Office, Washington, D.C. (April 1, 1991) Code of Federal Regulations 21 CFR 600-680
60. U.S. Government Printing Office, Washington, D.C. (April 1991) Code of Federal Regulations 21 CFR 210-211
61. United States Pharmacopeia Convention, Inc. (1990) U.S. Pharmacopeia XXII. Walter, J. and Werner, R. G. (1993) Regulatory Requirements and Economic Aspects in Downstream Processing of Biotechnically Engineered Proteins for Parenteral Application as Pharmaceuticals. In: Downstream Processing, Recovery and Purification of Proteins. A Handbook of Principles and Practice (Kroner, K.H., Papamichael, N. and Schütte, A., eds.), Carl Hanser Verlag, München
62. Walter, J., Werz, W. and Berthold, W. (1992) Virus Removal and Inactivation-Concept and Data for Process Validation of Downstream Processing, Biotech Forum Europe, 9,560-564
63. Walter, J., Werz, W., McGoff, P., Werner, R.G., Berthold, W. (1991) Virus Removal/Inactivation in Downstream Processing. In: Animal Cell Technology: Developments, Processes and Products (Spier, R.E., Griffiths, J.B. and MacDonald, C., eds.), Butterworth-Heinemann Ltd. Linacre House, Jordan Hill, Oxford OX2 8DP, pp 624-634
64. WHO Study Group (1987) Acceptability of cell substrates for production of Biologicals. Geneva: World Health Organization Technical Report Series 747, pp 1-29
65. World Health Organization (1991) Proposed Requirements for Monoclonal Antibodies for Clinical Use in Humans (Requirements for Biological Substances No. 48), Technical Report BS/91.1657
66. World Health Organization, Geneva (1987) Acceptability of all substrates for production of biologicals. Report of a WHO Study Group. Technical Report, Series 747